Multiplex Digital Methylation-Specific PCR for Noninvasive Screening of Lung Cancer

Area of Science:

• Biomarker Discovery
• Molecular Diagnostics
• Oncology

Background:

• Liquid biopsies offer noninvasive cancer detection via cell-free DNA (cfDNA).
• Low circulating tumor DNA (ctDNA) fractions necessitate sensitive, multiplexed biomarker panels.
• Existing methods like PCR and digital PCR (dPCR) have limitations in multiplexing and sensitivity.

Purpose of the Study:

• To develop and validate the first multiplex digital methylation-specific PCR (mdMSP) platform.
• To enable simultaneous analysis of four methylation biomarkers for non-small cell lung cancer (NSCLC) detection.
• To assess the clinical utility of mdMSP for early-stage NSCLC identification in liquid biopsy specimens.

Main Methods:

• Development of a novel mdMSP platform utilizing a microfluidic device with 40,160 nanowells across four independent modules.
• Analytical validation of the mdMSP platform for sensitivity and specificity.
• Clinical validation using 72 low-volume liquid biopsy specimens from patients with indeterminate pulmonary nodules.

Main Results:

• The mdMSP platform achieved multiplex detection with analytical specificities as low as 0.0005%.
• Demonstrated superior clinical performance compared to traditional methylation-specific PCR (MSP) assays.
• Successfully identified early-stage NSCLC in liquid biopsy samples.

Conclusions:

• The developed mdMSP platform is a sensitive and specific tool for liquid biopsy-based NSCLC detection.
• mdMSP offers improved clinical utility for noninvasive diagnosis of early-stage NSCLC.
• This technology advances the potential of liquid biopsies for cancer screening and diagnosis.